BioMimetic Therapeutics (BMTI)
|
8.75
+0.09 (+1.04%)
|
|
|
|
BMTI additional information
Market Data powered by QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Filings and Fundamentals by Morningstar, Insiders by Vickers (USA) and SEDI(CDN), analyst ratings by Zacks.
BMTI Profile
•
Exchange
NASDAQ
•
Held by these Mutual Funds
TCW Small Cap Growth I
ING Legg Mason ClearBridge Agrsv Gr I
Legg Mason ClearBridge Var Agrsv Gr I
iShares Nasdaq Biotechnology
Met Invt Ser LM ClearBridge Agrsv Gr E
Principal SmallCap Growth II Inst
iShares Russell 2000 Growth Index
Vanguard Extended Market Idx
Forward Growth A
CREF Stock
ING Legg Mason ClearBridge Agrsv Gr I
Legg Mason ClearBridge Var Agrsv Gr I
iShares Nasdaq Biotechnology
Met Invt Ser LM ClearBridge Agrsv Gr E
Principal SmallCap Growth II Inst
iShares Russell 2000 Growth Index
Vanguard Extended Market Idx
Forward Growth A
CREF Stock
•
Executives
Dr. Samuel E. Lynch D.M.D. M.Sc.
52
Founder Chief Exec. Officer Pres and Director
Mr. Lawrence E. Bullock
Chief Financial Officer
Principal Accounting Officer and Corp. Sec.
Dr. Russell Pagano Ph.D.
VP of Regulatory & Clinical Affairs
Mr. Harvey L. Kellman MBA
Exec. VP
Mr. Scott Ludecker r>VP of Global Sales & Marketing
52
Founder Chief Exec. Officer Pres and Director
Mr. Lawrence E. Bullock
Chief Financial Officer
Principal Accounting Officer and Corp. Sec.
Dr. Russell Pagano Ph.D.
VP of Regulatory & Clinical Affairs
Mr. Harvey L. Kellman MBA
Exec. VP
Mr. Scott Ludecker r>VP of Global Sales & Marketing
•
Employee Count
75
Special Offers
Competitors
BMTI earnings
Date
Actual
Expected
Prev Yr Qtr
11/5/2012
-0.16
-0.23
-0.25
8/2/2012
-0.23
-0.22
-0.29
5/9/2012
-0.22
-0.23
-0.28
